A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
DSM-5 provides standardized diagnostic criteria organized by symptom clusters, severity specifiers, and dimensional features. It reflects a shift toward dimensional assessment while maintaining categorical thresholds for clinical utility.
From your work on clinical assessment, you know that diagnosis begins with systematic information gathering. The DSM-5 is the framework that converts that information into a standardized, communicable label — but understanding *how* it works reveals both its power and its limitations. The DSM does not explain disorders or identify causes; it describes them. Its criteria are operational definitions based on observable symptoms and their duration, frequency, and functional impact — not on biology or etiology. Two patients with completely different life histories, brain chemistry, and vulnerabilities can receive the same diagnosis because their symptoms match the same checklist.
Most DSM-5 diagnoses use polythetic criteria: you need a minimum number from a symptom list, but not every symptom. A patient with major depressive disorder (MDD) must have depressed mood *or* anhedonia as anchor symptoms, plus four or more from a list of seven others (sleep change, appetite change, fatigue, concentration difficulty, psychomotor changes, guilt/worthlessness, suicidal ideation). This means two people who both qualify for MDD may share as few as two symptoms — which raises important questions about diagnostic homogeneity and treatment matching. The polythetic structure trades precision for coverage, capturing real-world clinical diversity within a single diagnostic category.
DSM-5 introduced more explicit dimensional and severity specifiers compared to its predecessors. Rather than simply diagnosing depression, clinicians now specify: mild, moderate, or severe; with or without psychotic features; with anxious distress; in partial or full remission; with peripartum onset; and so on. Cross-cutting symptom measures — brief questionnaires covering sleep, anxiety, substance use, suicidality, and psychosis across all disorders — allow clinicians to capture clinically important features that don't fit into any specific diagnosis. Together, these additions represent a partial move toward dimensional thinking: the idea that psychopathology is better understood on continua than as discrete categories.
The ongoing tension in DSM-5 is between clinical utility and validity. Categorical diagnoses are useful for communication, treatment decisions, billing, and research participant selection — but the underlying biology of mental disorders does not always respect diagnostic boundaries. Depression and anxiety overlap heavily in both symptom presentation and neurobiology. The same genetic risk factors appear across multiple diagnoses. Some researchers advocate replacing DSM categories with dimensional frameworks like the HiTOP model (Hierarchical Taxonomy of Psychopathology) or the NIMH's RDoC (Research Domain Criteria), which organize psychopathology around behavioral and neurobiological dimensions. Understanding DSM-5 means appreciating both what it delivers — a shared clinical language — and what it cannot do: explain why disorders exist or guarantee biologically homogeneous groups.